



IFW

PATENT
Customer No. 22,428
Attorney Docket No. 080618-0237

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John P. Cooke et al.
Title: ENHANCEMENT OF VASCULAR FUNCTION BY MODULATION
OF ENDOGENOUS NITRIC OXIDE PRODUCTION OR ACTIVITY
Appln. No.: 10/618,835
Filing Date: 07/15/2003
Examiner: J. Russel
Art Unit: 1654

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the Examiner's attention the documents on the attached form PTO/SB/08. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Non-English language documents

EP 0 511 118 A1 (C9): A Derwent Abstract of this document was filed in an IDS on May 19, 2004. According to the abstract, U.S. Pat. No. 5,352,695 (also filed May 19, 2004 as B2) is in the same family.

FR 2 507 892 (C14): Attached is UK Patent Application GB 2,100,982, in English, identified in Derwent abstract as the British counterpart application (C14a).

The documents submitted were cited in pleadings in the litigation known to the Office, and documents not submitted here are believed to be of record. The pleadings submitted with this paper are as follows:

1. October 13, 2003 Letter Brief from Dina Grinsphun to Judge Ware appending two opinions which affect Daily Wellness' motion for summary judgment;
2. Order Denying Defendant's Request that the Court Identify Terms At Issue; Setting Case Management Conference; Denying Without Prejudice Defendant's Motion for Summary Judgment;
3. Herbalife's Preliminary Invalidity Contentions served in *Unither v. Herbalife*;
4. Herbalife's Preliminary Invalidity Contentions served in *Herbalife v. Unither*;
5. Defendant Daily Wellness' Preliminary Invalidity Contentions Pursuant to Patent Local Rule 3-3;
6. Defendant Daily Wellness' Supplemental Preliminary Invalidity Contentions;

7. Defendant ANB's Preliminary Invalidity Contentions Pursuant to Patent Local Rule 3-3; and

8. Defendant ANB's Supplemental Preliminary Invalidity Contentions.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents are not "prior art" under United States law, then Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 05-21-2004

FOLEY & LARDNER LLP
Customer Number: 22428

Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By Sean A. Passino (45,943)
SEAN A. PASSINO
Stephen B. Maebius
Attorney for Applicants
Registration No. 35,264
FOR

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

MAY 21 2004

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substantive form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: May 21, 2004

(use as many sheets as necessary)

Sheet 1 of 15

Complete if Known

Application Number	10/618,835
Filing Date	07/15/2003
First Named Inventor	John P. Cooke
Group Art Unit	1654
Examiner Name	J. Russel
Attorney Docket Number	080618-0237

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	C1	2002/0091160	A1	COOKE, et al.	02-01-2002	
	C2	5,026,721		DUDRICK, et al.	06-25-1991	
	C3	5,028,627		KILBOURN, et al.	07-02-1991	
	C4	6,117,872		MAXWELL, et al.	09-12-2000	
	C5	6,337,321		COOKE, et al.	01-08-2002	
	C6	6,552,074		KIMOTO, et al.	04-22-2003	
	C7	6,646,006		COOKE, et al.	11-11-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	C8	EP	0 259 167 A2		Millman	03-09-1988		
	C9	EP	0 511 118 A1		N'Guyen	10-28-1992		
	C10	EP	511 587 A1		Moriyama et al.	11-04-1992		
	C11	EP	0 546 796 A1		Sonaka et al.	06-16-1993		
	C12	WO	98/18491		Burgstiner	05-07-1998		
	C13	ZA	9410015 A		Davis et al.	11-08-1995		
	C14	FR	2 507 892		Brugioni et al.	12-24-1982		
	C14a	GB	2 100 982		Brugioni et al.	06-22-1982		
	C15	WO	85/00517		Niebes et al.	02-14-1985		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C16	Adams et al., "Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease" <i>Atherosclerosis</i> , 1997, 129(2):261-69.	
	C17	Adams et al., "Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C," <i>J. Amer. Coll. Cardiol.</i> , 1997, 29(3):491-97.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 (use as many sheets as necessary)				Application Number	10/618,835
				Filing Date	07/15/2003
				First Named Inventor	John P. Cooke
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	2	of	15	Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C18	Aimasheva et al., "Donor of nitric oxide improves, while NO-synthase inhibitor impairs resistance and adaptation to strenuous physical exercise," <i>Bulletin of Exp. Biol. and Med.</i> , 1998, 4:336-339.	
	C19	Aisaka et al., "N ^G -monomethyl-L-arginine, an inhibitor of endothelium-derived nitric oxide synthesis, abbreviates acetylcholine-induced vasodilatation in the guinea-pig" in <i>Nitric Oxide from L-arginine: a Bioregulatory System</i> (S. Moncada and E.A. Higgs, eds.), 1990, Chapter 40, pp. 379-384.	
	C20	Aisaka et al., "Modulation of cardiovascular function by L-arginine-derived nitric oxide" <i>Frontiers and new horizons in amino acid research</i> (K. Takai, ed.), 1992, 437-442.	
	C21	Aisaka et al., "Regulation of vascular resistance by L-arginine-derived nitric oxide," <i>J. Pharmacobio-Dyn.</i> , 1992, 15:s-60.	
	C22	Alba-Roth et al., "Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion," <i>J. Clin. Endocrinol. Metab.</i> , 1988, 67(6):1186-89.	
	C23	Amrani et al., "Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart," <i>J. Physiol.</i> , 1992, 456:681-87.	
	C24	Aoyama et al., "Effects on liver and serum lipids of dietary supplements of methionine and excess lysine given to previously-starved rats," <i>British J. Nutr.</i> , 1983, 50(3):627-36.	
	C25	Barbul et al., "Arginine" in <i>Nutrition in Critical Care</i> (Gary Zaloga ed.), 1994, Chapter 6, pp. 107-21.	
	C26	Barbul A., "Physiology and pharmacology of arginine" in <i>Nitric Oxide from L-Arginine: A Bioregulation System</i> (Moncada, S. and Riggs, E.A., eds.), 1990, Chapter 33, pp. 3 17-29.	
	C27	Barbul A., "Arginine and immune function," 1999, <i>Nutr.</i> 6(1):53-62.	
	C28	Barbul et al., "Arginine: a thymotropic and wound-healing promoting agent," 1977, <i>Surg. Forum.</i> 28:101-103.	
	C29	Barclay et al., "The role of blood flow in limiting maximal metabolic rate in muscle," 1975, <i>Med Sci Sports.</i> 7(2):1 16-119.	
	C30	Baumier et al., "Arginine: new and exciting developments for an 'old' amino acid," 1996, <i>Biomed. Environ. Sci.</i> 9(2-3):296-315.	
	C31	Bellamy et al., "Oral L-arginine improves exercise tolerance and flow-related endothelial dysfunction in microvascular angina," 1996, Abstract No. 2478, <i>Suppl. Circulation</i> 94(8):1-425.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Sheet	3	of	15
		Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C32	Bissell, "Porphyria," Textbook of Medicine (ed. Wyngaarden and Smith), W.B. Saunders Co., Harcourt Brace Jovanovich Inc. Philadelphia, 1988, pp. 1182-89.	
	C33	Blomqvist, "Cardiovascular adaptations to physical training," 1983, Annu. Rev. Physiol. 45:169-89.	
	C34	Blum et al., "Oral L-arginine in patients with coronary artery disease on medical management," 2000, Circulation 101:2160-64.	
	C35	Bode-Boger et al., "Exercise increases systemic nitric oxide production in men," 1994, Cardiovasc. Risk. 1(2):173-78.	
	C36	Bode-Boger et al., "L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects," 1994, Clin. Sci. (Lond) 87(3):303-10.	
	C37	Boger et al., "L-arginine increases nutritive muscular blood flow determined by positron emission tomography (PET) in patients with peripheral arterial occlusive disease," 1996, Abstract No. 3176, Suppl. Circulation 94(8):1-543.	
	C38	Böger et al., "Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin," 1997, Circulation 96(4):1282-90.	
	C39	Bosaller et al., "Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta" 1987, J. Clin. Invest. 79(1):170-74.	
	C40	Candipan et al., "Regression or progression. Dependency on vascular nitric oxide" Arterioscler. Thromb. Vasc. Biol. 1996, 16(1):44-50.	
	C41	Caru et al., "Regional flow responses to exercise" Chest 1992, 101(5 Suppl):223S-225S.	
	C42	Castillo et al., "Plasma arginine, citrulline, and ornithine kinetics in adults, with observations on nitric oxide synthesis" Am. J. Physiol. 1995, 268: E360-E367.	
	C43	Castillo et al., "Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension" Pediatr. Res. 1995, 38(1):17-24.	
	C44	Castillo et al., "Endothelium-dependent vasodilatation in rat aorta is mainly mediated by nitric oxide" Proc. West. Pharmacol Soc. 1997, 40:39-40.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Date Submitted: May 21, 2004		Attorney Docket Number	080618-0237
(use as many sheets as necessary)			
Sheet	4	of	15

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C45	Castillo et al., "Dietary arginine uptake by the splanchnic region in adult humans" Am J Physiol. 1993, 65(4 Pt 1):E532-39.	
	C46	Castillo et al., "Splanchnic metabolism of dietary arginine in relation to nitric oxide synthesis in normal adult man" Proc. Natl. Acad. Sci. USA 1993, 90(1):193-97.	
	C47	Castillo et al., "Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets" Proc. Natl. Acad. Sci. USA 1993, 90:7749-53.	
	C48	Castillo et al., "Plasma arginine kinetics in adult man: response to an arginine-free diet" Metabolism 1994, 43(1):114-22.	
	C49	Ceremuzkynski et al., "L-arginine improves exercise capacity in patients with stable angina" Supplement to J. of Am. College of Cardiology, 1997, 29(2): Supp. A. Abstract 962-94.	
	C50	Ceremuzynski et al., "Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris" Am. J. Cardiol. 1997, 80(3):331-33.	
	C51	Chauhan et al., "Aging-associated endothelial dysfunction in humans is reversed by L-arginine" J. Amer. Coll Cardiol. 1996, 28(7):1796-1804.	
	C52	Chen et al., "L-arginine prevents hypertension in salt-sensitive (SS/Jr) Dahl/Rapp rats" Clinical Research 1991, 39:379A.	
	C53	Chen et al., "Hypertensive Nephrosclerosis in the Dahl/Rapp Rat: Initial Sites of Injury and Effect of Dietary L-Arginine Supplementation" Laboratory Investigation 1993, 68(2):174-184.	
	C54	Chen et al., "Effects of chronic treatment with L-arginine on atherosclerosis in ApoE knockout and ApoE/inducible NO synthase double-knockout mice" Arterioscler. Thromb. Vasc. Biol. 2003, 23:97-103.	
	C55	Cheng et al., "L-arginine in the management of cardiovascular diseases" Ann Pharmacother, 2001, 35(6):755-64.	
	C56	Chester et al., "Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries" Lancet 1990, 336(8720):897-900.	
	C57	Chester et al., "The role of nitric oxide in mediating endothelium dependent relaxations in the human epicardial coronary artery" Int J Cardiol. 1990, 29(3):305-09.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>				Application Number	10/618,835
				Filing Date	07/15/2003
				First Named Inventor	John P. Cooke
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	5	of	15	Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C58	Church et al., "Hypertension and renal impairment as complications of acute porphyria" Nephrol Dial Transplant. 1992, 7(10):986-90.	
	C59	Cooke et al., "Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine" Basic Res Cardiol., 1991, 86 Suppl 2:173-81.	
	C60	Cooke J.P., "A peculiar result and a fanciful hypothesis regarding L-arginine" Atheroscler. Thromb. Vasc. Biol. 2003, 23:1128-31.	
	C61	Creager et al., "L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans" Supplement to Circulation 1990, 82:III-346, 1248-1253.	
	C62	Cynober et al., "Arginine metabolism in mammals" J. Nutr. Biochem. 1995, 6:402-13.	
	C63	Davies et al., "Combination therapy of cholesterol reduction and L-arginine supplementation controls accelerated vein graft atheroma" Ann. Vasc. Surg. 1999, 13(5):484-93.	
	C64	de Graaf JC et al., "Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions". Circulation 1992, (6):2284-90.	
	C65	Deguchi et al., "L-Arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells". J. Biol. Chem. 1982, 257(17):10147-51.	
	C66	Dhanakoti et al., "Net renal arginine flux in rats is not affected by dietary arginine or dietary protein intake" Nutrient Metabolism 1992, 122(5):1127-34.	
	C67	Dubois-Rande, Jean-Luc et al., "L-arginine improves endothelium-dependent relaxation of conductance and resistance coronary arteries in coronary artery disease" J. of Cardio Pharm. 1992, 20(Suppl. 12):S211-S213.	
	C68	Edmonds et al., "Urea cycle metabolism: effects of supplemental ornithine or citrulline on performance, tissue amino acid concentrations and enzymatic activity in young pigs fed arginine-deficient diets" Anim. Sci. 1987, 65(3):706-16.	
	C69	Eklund et al., "Effects of the Source of Dietary Protein on Serum Lower Density Lipoprotein (VLDL + LDL) and Serum Tocopherol Levels in Female Rats" J. Nutr. 1980, 110(12):2321-35.	
	C70	Elder et al., "The acute porphyrias" Lancet. 1997 349(9065):1613-17.	
	C71	Elder et al., "Treatment of acute porphyria" Hosp Med. 2001, 62(7):422-25.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Sheet	6	of	15
		Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C72	Feng Q., et al., "Endothelium-derived relaxing factor (EDRF) and nitric oxide (NO). I. Physiology, pharmacology and pathophysiological implications" Clin. Physiol. 1990, (5):407-26.	
	C73	Freiman et al., "Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates," Circ Res. 1986, 58(6):783-89.	
	C74	Frick et al., "Cardiovascular dimensions and moderate physical training in young men" J Appl. Physiol. 1970, 29(4):452-55.	
	C75	Furchgott et al., "Interactions of endothelial cells and smooth muscle cells of arteries" Chest. 1985, 88(4 Suppl):210S-213S.	
	C76	Martin et al., "Depression of contractile responses in rat aorta by spontaneously released endothelium-derived relaxing factor" Pharmacol. Exp. Ther. 1986, 237(2):529-38.	
	C77	Furchgott et al., "Evidence for endothelium-dependent vasodilation of resistance vessels by acetylcholine" Blood Vessels. 1987, 24(3):145-49.	
	C78	Furchgott et al., "Evidence supporting the proposal that endothelium-derived relaxing factor is nitric oxide" Thrombosis Research 1987, Supp. VII:5.	
	C79	Furchgott et al., "Evidence that the endothelium-derived relaxing factor of rabbit aorta is nitric oxide" Dept. of Pharmacology, SUNY Health Science Center at Brooklyn, NY, 1988, 77-84.	
	C80	Furchgott et al., "Endothelium-derived relaxing and contracting factors" FASEB J. 1989, 3(9):2007-18.	
	C81	Furchgott et al., "Interactions of superoxide and hydrogen peroxide with nitric oxide and EDRF in the regulation of vascular tone" Endothelium-Derived Factors and Vascular Functions (T. Masaki, ed.), 1994, pp. 3-11.	
	C82	Furchgott RF et al., "Endothelial cells as mediators of vasodilation of arteries" J Cardiovasc Pharmacol. 6 Suppl 1984, 2:S336-43.	
	C83	Furchgott RF, "The pharmacology of vascular smooth muscle" Pharmacol Rev. 1955, 7(2):183-265.	
	C84	Furchgott RF, "A research trail over half a century" Ann. Rev. Pharmacol. Toxicol. 1995, 35:1-27.	
	C85	Furchgott RE, Bhadrakom S, "Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs" J. Pharmacol. Exp. Ther. 1953, 108(2):129-43.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Date Submitted: May 21, 2004		Attorney Docket Number	080618-0237
(use as many sheets as necessary)			
Sheet	7	of	15

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C86	Furchgott, RF, "The role of endothelium in the responses of vascular smooth muscle to drugs" Ann. Rev. Pharmacol. Toxicol. 1984, 24:175-97.	
	C87	Furchgott, RF, "The 1989 Ulf von Euler lecture. Studies on endothelium-dependent vasodilation and the endothelium-derived relaxing factor" Acta Physiol. Scand. 1990, 139(2):257-70.	
	C88	Furchgott, RF, "Introduction to EDRF Research" J. Cardiovascular Pharmacology Vol. 22, Supplement 7, 1993, pp. S1-S2.	
	C89	Furchgott, RF, "The discovery of endothelium-dependent relaxation" Supplement to Circulation 1993, 87:V-3 - V-8.	
	C90	Furchgott, RF, "The Discovery of Endothelium-Derived Relaxing Factor and Its Importance in the Identification of Nitric Oxide" JAMA 1996, 276(14) 1186-88.	
	C91	Furchgott, RF, "Discovery of endothelium-derived relaxing factor and its identification as nitric oxide" Endothelium, Nitric Oxide, and Atherosclerosis (Panza et al., eds.), 1999, Chapter 1, pp. 3-11.	
	C92	Furchgott, RF, "Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide" Biosci. Rep. 1999, 19(4):235-51.	
	C93	Ghigo et al., "Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects" J. Endocrinol Invest. 1994, 17(2): 113-22.	
	C94	Gordon, "The acute porphyrias" Brain Dev. 1999, 21(6):373-77.	
	C95	Grossman et al., "The Effects of External Calcium Concentration on the Distribution and Exchange of Calcium in Resting and Beating Guinea-Pig Auricles" J. Pharmacol. Exp. Ther. 1964, 143:107-19.	
	C96	Grossman et al., "The Effects of Frequency of Stimulation and Calcium Concentration on CA45 Exchange and Contractility on the Isolated Guinea-Pig Auricle" J Pharmacol Exp Ther. 1964, 143:120-30.	
	C97	Grossman et al., "The Effects of Various Drugs on Calcium Exchange in the Isolated Guinea-Pig Left Auricle" J. Pharmacol. Exp. Ther. 1964, 145:162-72.	
	C98	Hecker et al., "The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine" Proc. Natl. Acad. Sci. USA 1990, 87(21):8612-16.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Sheet	8	of	15
		Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C99	Henderson, (St Cyres lecture) "Endothelium in control," Br. Heart J. 1991, 65(3):116-25.	
	C100	Hishikawa et al., "L-arginine-induced hypertension" Lancet 1991, 337:683-84.	
	C101	Hishikawa et al., "L-arginine as an antihypertensive agent" J. of Cardio. Pharm. 1992, 22 (Suppl 12): S196-7.	
	C102	Hurson et al., "Metabolic effects of arginine in a healthy elderly population" JPEN J. Parenter. Enteral. Nutr. 1995, 19(3):227-30.	
	C103	Ignarro et al., "Alteration of endothelium-dependent arterial relaxation by arginine analogs and arginine depletion" Endothelium-Derived Relaxing Factors (Rubanyi et al., eds.), 1990, pp. 64-74.	
	C104	Ignarro, "Endothelium-derived nitric oxide: actions and properties" FASEB J. 1989, 3(1):31-36.	
	C105	Ignarro, "Biosynthesis and metabolism of endothelium-derived nitric oxide" Annu Rev Pharmacol Toxicol. 1990, 30:535-60.	
	C106	Ignarro, "Nitric oxide. A novel signal transduction mechanism for transcellular communication" Hypertension 1990, 16(5):477-83.	
	C107	Ikeda et al., "Dietary N ^G -nitro-L-arginine induces sustained hypertension in normotensive Wistar-Kyoto rats" Clin. and Exper. Pharmacol. and Physiol. 1992, 19:583-86.	
	C108	Kauppinen, "Management of the acute porphyrias" Photodermatol. Photoimmunol. Photomed. 1988, 14(2):48-51.	
	C109	Kilbourn et al., "Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis" Biochem. Biophys. Res. Commun. 1990, 15:172(3):1132-38.	
	C110	Kilbourn et al., "Inhibition of interleukin-1- β -induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1- α -induced hypotension by N omega-amino-L-arginine" J. Natl. Cancer Inst. 1992, 84(13):1008-16.	
	C111	Koifman et al., "Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure" J. Am. Coll. Cardiol. 26(5):1251-56.	
	C112	Kordac, et al., "Changes of myocardial functions in acute hepatic porphyrias. Role of heme arginate administration," Annals of Medicine 1989, 21(4):273-76.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>				Application Number	10/618,835
				Filing Date	07/15/2003
				First Named Inventor	John P. Cooke
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	9	of	15	Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	C113	Lais, et al., "Mechanism of vascular hyperresponsiveness in the spontaneously hypertensive rat," Circ Res. 1975, 36(6 Suppl 1):216-22.		
	C114	Lane, P., et al., "Cell signaling by nitric oxide," Semin Nephrol. 1999, 19(3):215-29.		
	C115	Leclercq-Meyer V., et al., "Calcium dependency of glucagon release: its modulation by nutritional factors," Am J Physiol 1979, 236(2):E98-104.		
	C116	Levenson, et al., "Citrulline replaces arginine as a dietary essential in rats; ornithine does not," Federation of American Societies for Experimental Biology: Federation Proceedings Abstracts 64 th Annual Meeting, Anaheim, California (Part I of Two Parts) 1980, 39(3):2421.		
	C117	Levere, et al., "Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats," Clin Invest. 1990, 86(1):213-9.		
	C118	Linden, et al., "Fate of haem after parenteral administration of haem arginate to rabbits," J. Pharm. Pharmacol. 1987, 39(2):96-102.		
	C119	Lip, et al., "The acute porphyrias," Br. J. Clin. Pract. 1993, 47(1):38-43.		
	C120	Luscher, et al., "Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats" Hypertension. 1988 11(6 Pt 2):573-8.		
	C121	Marcelin et al., "Modulating Role of Nitric Oxide Pathway on the Synthesis of PGI ₂ in Rat Endothelial Cells in Culture," Hypertension 1999, 33(4):1297.		
	C122	Marin et al., "Role of endothelium-formed nitric oxide on vascular responses" Gen Pharmacol. 1990 21(5):575-87.		
	C123	Marshall et al., "Endothelium-derived relaxing factors. A perspective from in vivo data" Hypertension 1990, 16(4):371-86.		
	C124	Martasek et al., "Properties of human kidney heme oxygenase: inhibition by synthetic heme analogues and metalloporphyrins" Biochem Biophys Res Commun. 1988, 157(2):480-87.		
	C125	Martasek et al., "Heme arginate lowers blood pressure in spontaneous hypertensive rats (SHR)" Clinical Research 1989, 37:553A.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>				Application Number	10/618,835
				Filing Date	07/15/2003
				First Named Inventor	John P. Cooke
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	10	of	15	Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	C126	Martasek et al., "Hemin and L-arginine regulation of blood pressure in spontaneous hypertensive rats" J. Am. Soc. Nephrol. 1991, 2(6):1078-84.		
	C127	Martin et al., "Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor" J. Pharmacol. Exp. Ther. 1986, 237(2):539-47.		
	C128	Maxwell et al., "Cardiovascular effects of L-arginine" Curr. Opin. Nephrol. Hypertens. 1998, 7:63-70 (review).		
	C129	Maxwell et al., "Limb blood flow during exercise is dependent on nitric oxide" Circulation 1998, 98(4):369-74.		
	C130	Maxwell et al., "Hypercholesterolemia impairs exercise capacity: Role of nitric oxide" (Stanford University draft), 1998, pp. 1-23 and 33-34.		
	C131	Maxwell et al., "Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar®" Vasc. Med. 2000, 5:11-19.		
	C132	Maxwell et al., "L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production" J. Appl. Physiol. 2001, 90(3):933-38.		
	C133	Merimee et al., "Arginine-initiated release of human growth hormone. Factors modifying the response in normal man" New Engl. J. Med. 1969, 280(24):1434-38.		
	C134	Milner JA, "Metabolic aberrations associated with arginine deficiency" J. Nutr. 1985, 115(4):516-23.		
	C135	Mitchell et al., "The generation of L-arginine in endothelial cells is linked to the release of endothelium-derived relaxing factor" Eur. J. Pharmacol. 1990, 176(2):253-54.		
	C136	Moncada and Higgs, "Endogenous nitric oxide: physiology, pathology and clinical relevance" Eur. J. Clin. Invest. 1991, 21(4):361-74.		
	C137	Moncada et al., "The L-arginine nitric-oxide pathway" The New England Journal of Medicine, 1993, 329(27):2002-12.		
	C138	Moncada S, et al., "Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication" Biochem Pharmacol. 1989, 38(11):1709-15.		
	C139	Moncada S, et al., "The biological significance of nitric oxide formation from L-arginine" Biochem. Soc. Trans. 1989, vol. 17(4):642-44.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>				Application Number	10/618,835
				Filing Date	07/15/2003
				First Named Inventor	John P. Cooke
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	11	of	15	Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C140	Moncada et al., "International Union of Pharmacology Nomenclature in Nitric Oxide Research" Pharmacol. Rev. 1997, 49(2):137-42.	
	C141	Moncada, "The first Robert Furchgott lecture: from endothelium-dependent relaxation to the L-arginine:NO pathway" Blood Vessels 1990, 27(2-5):208-17.	
	C142	Moore et al., "Therapy of the acute porphyrias" Clin. Biochem. 1989, 22(3):181-88.	
	C143	Nava et al., "NO and Hypertension" in Nitric Oxide and the Kidney: Physiology and Pathophysiology (Goligorsky and Gross, eds.), Chapter 18, pp. 368-383.	
	C144	Niebauer et al., "Impaired aerobic capacity in hypercholesterolemic mice: partial reversal by exercise training" Am. J. Physiol. 1999, 276:H1346-H1354.	
	C145	Nogowski L. et al., "Arginine, administered in various ways, as a stimulator of insulin secretion in the rabbit" Horm. Metab. Res. 1986, 18(11):730-33.	
	C146	Numano et al., "Antiplatelet therapy for atherosclerotic disorders" Ann. NY Acad. Sci. 1990, 598:356-67.	
	C147	Oomen et al., "Arginine intake and risk of coronary heart disease mortality in elderly men" Arterioscler. Thromb. Vasc. Biol. 2000, 20:2134-39.	
	C148	Osborne et al., "Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits" Am. J. Physiol. 1989, 256:C591-C597.	
	C149	Palmer et al., "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor" Nature 1987, 327:524-26.	
	C150	Palmer et al., "The biological significance of nitric oxide formation from L-arginine" Biochem. Soc. Trans. 1989, 17(4):642-44.	
	C151	Park et al., "Effects of dietary protein and amino acids on the metabolism of cholesterol-carrying lipoproteins in rats" J. Nutr. 1982, 112(10):1892-98.	
	C152	Park et al., "Nitric oxide is a mediator of hypoxic coronary vasodilatation. Relation to adenosine and cyclooxygenase-derived metabolites" Circ. Res. 1992, 71(4):992-1001.	
	C153	Patel et al., "L-arginine administration normalizes pressure natriuresis in hypertensive Dahl rats" Hypertension 1993, 22(6):863-69.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/618,835	
				Filing Date	
				07/15/2003	
				First Named Inventor	
Date Submitted: May 21, 2004				John P. Cooke	
(use as many sheets as necessary)				Group Art Unit	
				1654	
				Examiner Name	
				J. Russel	
Sheet 12 of 15				Attorney Docket Number	
				080618-0237	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C154	Pearson and Shaw, "Life Extension: A Practical Scientific Approach," Warner Books, Inc., New York 1982, pp. 307-21, 460-85.	
	C155	Pizcueta et al., "Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension" Br J Pharmacol. 1992, 105(1):184-90.	
	C156	Pomerantz et al., "Cholesterol enrichment of arterial smooth muscle cells upregulates cytokine-induced nitric oxide synthesis" Biochem. and Biophys. Res. Comm. 1993, 191(1):103-09.	
	C157	Preli et al., "Vascular effects of dietary L-arginine supplementation" Atherosclerosis 2002, 162:1-15.	
	C158	Radomski et al., "An L-arginine/nitric oxide pathway present in human platelets regulates aggregation" Proc Natl Acad Sci USA. 1990, 87(13):5193-97.	
	C159	Radomski et al., "Regulation of vascular homeostasis by nitric oxide" Thromb. Haemost. 1993, 700(1):36-41.	
	C160	Radomski MW et al., "Modulation of platelet aggregation by an L-arginine-nitric oxide pathway" Trends Pharmacol. Sci. 1991, (3):87-8.	
	C161	Rector et al., "Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure" Circulation 1996, 93(12):2135-41.	
	C162	Reynolds et al., "Immunomodulatory mechanisms of arginine" Surgery 1988, 104(2):142-51.	
	C163	Rubanyi et al., "Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor" Am. J. Physiol. 1986, 250:H822-H827.	
	C164	Rubanyi, "The role of endothelium in cardiovascular homeostasis and diseases" J. of Cardio. Pharm. 1993, 22 (Suppl.) S1-S14.	
	C165	Sakuma et al., "Identification of arginine as a precursor of endothelium-derived relaxing factor" Proc. Natl. Acad. Sci. USA 1988, 85(22):8664-67.	
	C166	Sakuma et al., "L-Arginine is a Precursor of Endothelium-Derived Relaxing Factor in Various Animal Species and Vascular Beds" in <u>Nitric Oxide from L-Arginine: A Bioregulatory System</u> (Moncada and Higgs, eds.) 1990, Chapter 49, pp. 445-49.	
	C167	Sanchez et al., "Testing a mechanism of control in human cholesterol metabolism: relation of arginine and glycine to insulin and glucagon" Atherosclerosis 1988, 71:87-92.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Sheet	13	of	15
		Attorney Docket Number	080618-0237

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C168	Sanchez et al., "Plasma amino acids and the insulin/glucagon ratio as an explanation for the dietary protein modulation of atherosclerosis" Medical Hypotheses 1991, 35:324-29.	
	C169	Schaffer et al., "Nitric oxide regulates wound healing" J. Surg. Res. 1996, 63(1):237-40.	
	C170	Schwarzacher et al., "Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty" Circulation 1997, 95(7):1863-69.	
	C171	Seifter et al., "Arginine: an essential amino acid for injured rats" Surgery 1978, (2):224-30.	
	C172	Sessa WC et al., "The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells" Proc. Natl. Acad. Sci. USA 1990, 87(21):8607-11.	
	C173	Shepherd et al., "Endothelium-Derived Relaxing (EDRF) and Contracting Factors (EJJCf) in the Control of Cardiovascular Homeostasis: The Pioneering Observations" <u>Cardiovascular Significance of Endothelium-Derived Vasoactive Factors</u> (G. Rubanyi ed.), 1991, Chapter 2, pp. 39-64.	
	C174	Smith et al., "Role of nitric oxide synthesis in the regulation of coronary vascular tone in the isolated perfused rabbit heart" Cardiovasc. Res. 1992, (5):508-12.	
	C175	Snyder et al., "Biological roles of nitric oxide" Sci. Am. 1992, 266(5):68-71, 74-77.	
	C176	Solangi et al., "L-arginine protects cyclosporin A-induced blood pressure elevation in spontaneous hypertensive rats" Clinical Research 1990, 38(2):349A.	
	C177	Steinsland OS et al., "Biphasic vasoconstriction of the rabbit ear artery" Circ. Res. 1973, (1):49-58.	
	C178	Suarez et al., "Modulation of the vascular response of isolated perfused rat kidney to phenylephrine by flow. Role of nitric oxide" Hypertension 1995, 25:1392.	
	C179	Tenenbaum et al., "L-Arginine: rediscovery in progress" Cardiology 1998, 90(3):153-59.	
	C180	Thadani et al., "Diagnosis and management of porphyria" BMJ. 2000, 17:320(7250):1647-51.	
	C181	Thomas G, et al., "Vasodilatory properties of mono-L-arginine-containing compounds" Biochem Biophys Res Commun. 1988, 154(1):332-38.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 21, 2004 <i>(use as many sheets as necessary)</i>		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Sheet 14 of 15	Attorney Docket Number	080618-0237	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C182	Togashi et al., "A central nervous system action of nitric oxide in blood pressure regulation" J. Pharmacol. Exp. Ther. 1992, 262(1):343-47.	
	C183	Umans et al., "Nitric oxide in the regulation of blood flow and arterial pressure" Annu. Rev. Physiol. 1995, 57:771-790.	
	C184	Vallance et al., "Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo" Cardiovasc. Res. 1989, 23(12):1053-7.	
	C185	Vallance et al., "Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man" Lancet 1989, 2(8670):997-1000.	
	C186	Vane et al., (Mechanisms of disease) "Regulatory functions of the vascular endothelium" New England J. Med. 1990, 323:27-36.	
	C187	Vane et al., "Endothelium-derived vasoactive factors and the control of the circulation" Seminars in Perinatology 1991, 15:4-10.	
	C188	Vane et al., "Control of the circulation by chemical mediators from the endothelium" J. Physiol. and Pharmacol. 1993, 44:5-36.	
	C189	Vane, "Control of the circulation by endothelial mediators," Inaugural G.B. West Memorial Lecture, Int. Arch. Allergy Immunol. 1993, 101(4):333-45.	
	C190	Vanhoutte et al., "Modulation of vascular smooth muscle contraction by the endothelium" Annu. Rev. Physiol. 1986, 48:307-20.	
	C191	Venho et al., "Arginine intake, blood pressure, and the incidence of acute coronary events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study" Am. J. Clin. Nutr. 2002, 76:359-64.	
	C192	Volin et al., "Heme arginate: effects on hemostasis" Blood 1988, 71(3):625-28.	
	C193	von der Leyen HE, et al., "Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene" Proc. Natl. Acad. Sci. USA 1995 92(4):1137-41.	
	C194	Waldman SA et al., "Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system" J Cardiovasc Pharmacol. 1988, 12 Suppl 5:S115-8.	
	C195	Waller et al., "Conditions for synthesis of antioxidative arginine-xylose maillard reaction products" Synthesis of Antioxidative Products 1983, pp. 125-40.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/618,835
		Filing Date	07/15/2003
		First Named Inventor	John P. Cooke
		Group Art Unit	1654
		Examiner Name	J. Russel
Date Submitted: May 21, 2004		Attorney Docket Number	080618-0237
(use as many sheets as necessary)			
Sheet	15	of	15

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C196	Wang et al., "Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit" J Am College Cardiol. 1994, 23(2):452-58.	
	C197	Wascher, "Oral L-arginine supplementation in chronic heart failure" Circulation 1997, 95(6):1674-75.	
	C198	Wennmalm, "Endothelial nitric oxide and cardiovascular disease" J. Intern. Med. 1994, 235(4):317-27.	
	C199	Weyrich et al., "The Role of L-Arginine in Ameliorating Reperfusion Injury After Myocardial Ischemia in the Cat" Circulation 1992, 86(1):279-88.	
	C200	Wiklund et al., "Modulatory role of endogenous nitric oxide in pulmonary circulation in vivo" Eur J Pharmacol. 1990 185(1):123-24.	
	C201	Windmueller et al., "Source and fate of circulating citrulline" Am. J. Physiol. 1981 241(6):E473-80.	
	C202	Wu et al., "Arginine metabolism: nitric oxide and beyond" Biochem. J. 1998 336:1-17.	
	C203	Wu et al., "Arginine nutrition and cardiovascular function" Am. Society Nutr. Sci. 2000, 130:2626-29.	
	C204	Zeiber et al., "Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis" Circulation 1991 83(2):391-401.	
	C205	Zeiber et al., "Endothelial Dysfunction of the Coronary Microvasculature Is Associated With Impaired Coronary Blood Flow Regulation in Patients With Early Atherosclerosis" Circulation 1991, 84(5):1984-92.	
	C206	Dialog Search Result for Normosang Synonyms. Chemsearch Database.	
	C207	European Porphyria Initiative, http://www.porphyria-europe.com , selected pages.	
	C208	Stedman's Medical Dictionary, The Williams and Wilkins Co. (23 rd Edition 1976), p. 1124.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.